PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 825 (xsd:integer)
nif:isString
  • Patient recruitment for this cohort included three phases: The first phase between December 2005 and December 2008 recruited adult HIV-positive patients, who were also either chronically infected by HCV at enrollment or had a negative HCV RNA test by PCR six months after ending HCV treatment (PEG-IFN),The second phase, from September 2011 to March 2016, recruited both individuals who spontaneously cleared HCV before the enrolment, and HIV-HCV infected patients who initiated HCV treatment with triple therapy (PEG-IFN +ribavirin + either telaprevir or boceprevir),The third phase, from May 2014 to November 2015, was an additional recruitment phase, where patients who were already receiving, or were scheduled to receive DAA within six months, were recruited.In France, PEG-IFN+ ribavirin first became available in 2000.
rdf:type